<i>In vitro</i> generated macrophages reflect the immunosuppressive phenotype of <i>in vivo</i> glioblastoma-associated macrophages

Glioblastoma (GBM) is the most common primary central nervous system tumor with a dismal prognosis and limited treatment options. Recent success utilizing immunotherapies for treating other solid tumors have been largely unsuccessful in GBM. One of the primary mechanisms of GBM immunotherapeutic resistance is because of excessive infiltration of myeloid cells that create an immunosuppressive tumor microenvironment (TME). Among these infiltrating myeloid cells, tumor-associated macrophages (TAMs), comprise a substantial portion of the TME and are associated with poor prognosis in GBM patients. Researchers have only recently begun to dissect the dynamics and complexity of TAMs. However, reliable and reproducible translational methods for generating GBM TAMs <i>in vitro</i> are lacking. Here, we have investigated an <i>in vitro,</i> reproducible murine-based model for bone marrow-derived, glioma-educated macrophages (gTAMs) and performed rigorous analysis to expand our understanding of gTAMs to provide a validated tool for investigating therapeutic response.

Authors

Institutions

Publication Details

Journal
OncoImmunology
Published
2026-01-25
DOI
https://doi.org/10.1080/2162402x.2025.2610562
Primary Topic
Immune cells in cancer
Type
article
Field-Weighted Citation Impact
0.00
Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
article

In vitro generated macrophages reflect the immunosuppressive phenotype of in vivo glioblastoma-associated macrophages

Matthew Nazzaro, Gregory K. Behbehani, Justin Lyberger, Mark Damante et al.
OncoImmunology
Immune cells in cancer
article

In vitro generated macrophages reflect the immunosuppressive phenotype of in vivo glioblastoma-associated macrophages

Matthew Nazzaro, Gregory K. Behbehani, Justin Lyberger, Mark Damante, ER Mardis, Susobhan Sarkar, Ella Juenger, Prajwal Rajappa, Mykyta Artomov
article en

Abstract

Glioblastoma (GBM) is the most common primary central nervous system tumor with a dismal prognosis and limited treatment options. Recent success utilizing immunotherapies for treating other solid tumors have been largely unsuccessful in GBM. One of the primary mechanisms of GBM immunotherapeutic resistance is because of excessive infiltration of myeloid cells that create an immunosuppressive tumor microenvironment (TME). Among these infiltrating myeloid cells, tumor-associated macrophages (TAMs), comprise a substantial portion of the TME and are associated with poor prognosis in GBM patients. Researchers have only recently begun to dissect the dynamics and complexity of TAMs. However, reliable and reproducible translational methods for generating GBM TAMs <i>in vitro</i> are lacking. Here, we have investigated an <i>in vitro,</i> reproducible murine-based model for bone marrow-derived, glioma-educated macrophages (gTAMs) and performed rigorous analysis to expand our understanding of gTAMs to provide a validated tool for investigating therapeutic response.

OncoImmunologyVol. 15(1)
Nationwide Children's Hospital (US), Cleveland Clinic (US), Rasmussen College (US), The Ohio State University Wexner Medical Center (US), Immune Regulation (United Kingdom) (GB), Neurological Surgery (US), The Ohio State University (US)
No poverty
Openalex Percentile: Top 78%
Immune cells in cancer
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.

<i>In vitro</i> generated macrophages reflect the immunosuppressive phenotype of <i>in vivo</i> glioblastoma-associated macrophages — Matthew Nazzaro, Gregory K. Behbehani, et al. · OncoImmunology (2026) | TGRS Research Map | TGRS